LIVIVO - Search results -

Search results

Result 1 - 10 of total 201

Search options

Article ; Online: Freud en de naleving van de darmkankerrichtlijn.

Linn, Sabine C

2018 Volume 162

Abstract: A recent study by Keikes et al. (Clin Colorectal Cancer. 2018;17:58-64) focused on adherence to the Dutch colorectal cancer guideline and concluded that adherence was suboptimal. This commentary puts their results in context. Guidelines are useful for ... ...

Title translation	Freud and colorectal cancer guideline adherence in the Netherlands.
Abstract	A recent study by Keikes et al. (Clin Colorectal Cancer. 2018;17:58-64) focused on adherence to the Dutch colorectal cancer guideline and concluded that adherence was suboptimal. This commentary puts their results in context. Guidelines are useful for those oncologists who lack time to study the original literature. Medical oncologists nowadays have become more and more specialised in a few tumour types, engage in continuous medical education, and discuss controversial issues at (inter)national meetings. Hence, skilled oncologists will not always follow guidelines where alternative choices are in the best interest of the patient. Especially in the metastatic setting, the patient's wishes, combined with balancing quality and quantity, consideration of co-morbidities, and a need to be cost-effective, may influence therapeutic choices and thereby results in best practice. Lack of adherence can have multiple reasons. For instance, the guideline might be outdated, it may not cover all therapeutic options, or oncologists may not be familiar with the guidelines.
MeSH term(s)	Colorectal Neoplasms ; Guideline Adherence ; Humans ; Netherlands ; Oncologists ; Surveys and Questionnaires
Language	Dutch
Publishing date	2018-07-05
Publishing country	Netherlands
Document type	Journal Article ; Comment
ZDB-ID	82073-8
ISSN	1876-8784 ; 0028-2162
ISSN (online)	1876-8784
ISSN	0028-2162
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Response to Klar and Adams.

Dackus, Gwen M H E / Jóźwiak, Katarzyna / Hauptmann, Michael / Linn, Sabine C

Journal of the National Cancer Institute

2021 Volume 114, Issue 1, Page(s) 167–168

MeSH term(s)	Aromatase Inhibitors ; Breast Neoplasms ; Female ; Humans ; Perimenopause ; Tamoxifen
Chemical Substances	Aromatase Inhibitors ; Tamoxifen (094ZI81Y45)
Language	English
Publishing date	2021-08-01
Publishing country	United States
Document type	Journal Article ; Comment
ZDB-ID	2992-0
ISSN	1460-2105 ; 0027-8874 ; 0198-0157
ISSN (online)	1460-2105
ISSN	0027-8874 ; 0198-0157
DOI	10.1093/jnci/djab153
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.131: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".

Koole, Simone N / Schouten, Philip C / van Driel, Willemien J / Sonke, Gabe S / Linn, Sabine C

International journal of cancer

2022 Volume 151, Issue 11, Page(s) 2057–2058

MeSH term(s)	Carcinoma, Ovarian Epithelial/drug therapy ; Cytoreduction Surgical Procedures/methods ; Female ; Genomics ; Humans ; Hyperthermia, Induced/methods ; Hyperthermic Intraperitoneal Chemotherapy ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/therapy
Language	English
Publishing date	2022-08-05
Publishing country	United States
Document type	Clinical Trial, Phase II ; Letter ; Comment
ZDB-ID	218257-9
ISSN	1097-0215 ; 0020-7136
ISSN (online)	1097-0215
ISSN	0020-7136
DOI	10.1002/ijc.34219
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 478: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 576: Show issues

Order via subito

Details ▾

Article ; Online: Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer.

Kok, Marleen / Horlings, Hugo M / Snaebjornsson, Petur / Chalabi, Myriam / Schumacher, Ton N / Blank, Christian U / Linn, Sabine C / van Dieren, Jolanda

JCO precision oncology

2021 Volume 1, Page(s) 1–3

Language	English
Publishing date	2021-12-31
Publishing country	United States
Document type	Journal Article
ISSN	2473-4284
ISSN (online)	2473-4284
DOI	10.1200/PO.17.00052
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation.

de Jong, Vincent M T / Pruntel, Roelof / Steenbruggen, Tessa G / Bleeker, Fonnet E / Nederlof, Petra / Hogervorst, Frans B L / Linn, Sabine C

Familial cancer

2022 Volume 22, Issue 2, Page(s) 151–154

Abstract: An inherited single nucleotide variant (SNV) in the 5'UTR of the BRCA1 gene c.-107A > T was ... the previously identified c.-107A > T SNV in BRCA1. We therefore can conclude that the germline SNV is not ...

Abstract	An inherited single nucleotide variant (SNV) in the 5'UTR of the BRCA1 gene c.-107A > T was identified to be related to BRCA1 promoter hypermethylation and a hereditary breast and ovarian cancer phenotype in two UK families. We investigated whether this BRCA1 variant was also present in a Dutch cohort of breast and ovarian cancer patients with tumor BRCA1 promoter hypermethylation. We selected all breast and ovarian cancer cases that tested positive for tumor BRCA1 promoter hypermethylation at the Netherlands Cancer Institute and Sanger sequenced the specific mutation in the tumor DNA. In total, we identified 193 tumors with BRCA1 promoter hypermethylation in 178 unique patients. The wild-type allele was identified in 100% (193/193) of sequenced tumor samples. In a large cohort of 178 patients, none had tumors harboring the previously identified c.-107A > T SNV in BRCA1. We therefore can conclude that the germline SNV is not pervasive in patients with tumor BRCA1 promoter hypermethylation.
MeSH term(s)	Female ; Humans ; Carcinogens ; DNA Methylation ; BRCA1 Protein/genetics ; Genes, BRCA1 ; Promoter Regions, Genetic ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Breast Neoplasms/genetics
Chemical Substances	Carcinogens ; BRCA1 Protein ; BRCA1 protein, human
Language	English
Publishing date	2022-09-16
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1502496-9
ISSN	1573-7292 ; 1389-9600
ISSN (online)	1573-7292
ISSN	1389-9600
DOI	10.1007/s10689-022-00314-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6099: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Challenges in the Use of DNA Repair Deficiency As a Biomarker in Breast Cancer.

Schouten, Philip C / Linn, Sabine C

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2015 Volume 33, Issue 17, Page(s) 1867–1869

MeSH term(s)	Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Biomarkers, Tumor/genetics ; Carboplatin/therapeutic use ; Cisplatin/therapeutic use ; Female ; Genomic Instability ; Humans ; Mastectomy, Segmental ; Neoadjuvant Therapy/methods ; Triple Negative Breast Neoplasms/drug therapy
Chemical Substances	Antineoplastic Agents ; BRCA1 Protein ; BRCA2 Protein ; Biomarkers, Tumor ; Carboplatin (BG3F62OND5) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2015-06-10
Publishing country	United States
Document type	Comment ; Editorial
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.2014.60.5501
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Immune landscape of breast tumors with low and intermediate estrogen receptor expression.

Voorwerk, Leonie / Sanders, Joyce / Keusters, Milou S / Balduzzi, Sara / Cornelissen, Sten / Duijst, Maxime / Lips, Esther H / Sonke, Gabe S / Linn, Sabine C / Horlings, Hugo M / Kok, Marleen

NPJ breast cancer

2023 Volume 9, Issue 1, Page(s) 39

Abstract: Immune checkpoint blockade (ICB) is currently approved for patients with triple-negative breast cancer (TNBC), whereas responses to ICB are also observed in a small subgroup of Estrogen Receptor (ER)-positive breast cancer. The cut-off for ER-positivity ( ...

Abstract	Immune checkpoint blockade (ICB) is currently approved for patients with triple-negative breast cancer (TNBC), whereas responses to ICB are also observed in a small subgroup of Estrogen Receptor (ER)-positive breast cancer. The cut-off for ER-positivity (≥1%) is based on likelihood of endocrine treatment response, but ER-positive breast cancer represents a very heterogeneous group. This raises the question whether selection based on ER-negativity should be revisited to select patients for ICB treatment in the context of clinical trials. Stromal tumor-infiltrating lymphocytes (sTILs) and other immune parameters are higher in TNBC compared to ER-positive breast cancer, but it is unknown whether lower ER levels are associated with more inflamed tumor microenvironments (TME). We collected a consecutive series of primary tumors from 173 HER2-negative breast cancer patients, enriched for tumors with ER expression between 1 and 99% and found levels of stromal TILs, CD8 + T cells, and PD-L1 positivity in breast tumors with ER 1-9% and ER 10-50% to be comparable to tumors with ER 0%. Expression of immune-related gene signatures in tumors with ER 1-9% and ER 10-50% was comparable to ER 0%, and higher than in tumors with ER 51-99% and ER 100%. Our results suggest that the immune landscape of ER low tumors (1-9%) and ER intermediate tumors (10-50%) mimic that of primary TNBC.
Language	English
Publishing date	2023-05-13
Publishing country	United States
Document type	Journal Article
ISSN	2374-4677
ISSN	2374-4677
DOI	10.1038/s41523-023-00543-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy.

van Aken, Evert S M / Beeker, Aart / Houtenbos, Ilse / Pos, Floris J / Linn, Sabine C / Elkhuizen, Paula H M / de Jong, Monique C

Cancer reports (Hoboken, N.J.)

2021 Volume 5, Issue 2, Page(s) e1470

Abstract: Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors have recently been approved for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer in association with endocrine therapy in postmenopausal women. Data on the ... ...

Abstract	Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors have recently been approved for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer in association with endocrine therapy in postmenopausal women. Data on the interaction of CDK4/6 inhibition and radiotherapy are scarce, but some studies show unexpected toxicity. Cases: We report three cases of unexpected severe or prolonged soft tissue, skin, and gastrointestinal toxicity in patients treated with a combination of radiotherapy and the CDK4/6 inhibitor palbociclib. Conclusion: These cases indicate a possible interaction between radiotherapy and palbociclib. Therefore, we recommend using radiotherapy cautiously when combined with CDK4/6 inhibitors.
MeSH term(s)	Bone Neoplasms/radiotherapy ; Bone Neoplasms/secondary ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Breast Neoplasms/radiotherapy ; Disease Progression ; Female ; Humans ; Middle Aged ; Pain Management ; Piperazines/adverse effects ; Postmenopause ; Protein Kinase Inhibitors/adverse effects ; Pyridines/adverse effects
Chemical Substances	Piperazines ; Protein Kinase Inhibitors ; Pyridines ; palbociclib (G9ZF61LE7G)
Language	English
Publishing date	2021-06-18
Publishing country	United States
Document type	Case Reports ; Journal Article
ISSN	2573-8348
ISSN (online)	2573-8348
DOI	10.1002/cnr2.1470
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.

Wang, Yuwei / Dackus, Gwen M H E / Rosenberg, Efraim H / Cornelissen, Sten / de Boo, Leonora W / Broeks, Annegien / Brugman, Wim / Chan, Terry W S / van Diest, Paul J / Hauptmann, Michael / Ter Hoeve, Natalie D / Isaeva, Olga I / de Jong, Vincent M T / Jóźwiak, Katarzyna / Kluin, Roelof J C / Kok, Marleen / Koop, Esther / Nederlof, Petra M / Opdam, Mark /

Schouten, Philip C / Siesling, Sabine / van Steenis, Charlaine / Voogd, Adri C / Vreuls, Willem / Salgado, Roberto F / Linn, Sabine C / Schmidt, Marjanka K

BMC medicine

2024 Volume 22, Issue 1, Page(s) 9

Abstract: Background: Due to the abundant usage of chemotherapy in young triple-negative breast cancer (TNBC) patients, the unbiased prognostic value of BRCA1-related biomarkers in this population remains unclear. In addition, whether BRCA1-related biomarkers ... ...

Abstract	Background: Due to the abundant usage of chemotherapy in young triple-negative breast cancer (TNBC) patients, the unbiased prognostic value of BRCA1-related biomarkers in this population remains unclear. In addition, whether BRCA1-related biomarkers modify the well-established prognostic value of stromal tumor-infiltrating lymphocytes (sTILs) is unknown. This study aimed to compare the outcomes of young, node-negative, chemotherapy-naïve TNBC patients according to BRCA1 status, taking sTILs into account. Methods: We included 485 Dutch women diagnosed with node-negative TNBC under age 40 between 1989 and 2000. During this period, these women were considered low-risk and did not receive chemotherapy. BRCA1 status, including pathogenic germline BRCA1 mutation (gBRCA1m), somatic BRCA1 mutation (sBRCA1m), and tumor BRCA1 promoter methylation (BRCA1-PM), was assessed using DNA from formalin-fixed paraffin-embedded tissue. sTILs were assessed according to the international guideline. Patients' outcomes were compared using Cox regression and competing risk models. Results: Among the 399 patients with BRCA1 status, 26.3% had a gBRCA1m, 5.3% had a sBRCA1m, 36.6% had tumor BRCA1-PM, and 31.8% had BRCA1-non-altered tumors. Compared to BRCA1-non-alteration, gBRCA1m was associated with worse overall survival (OS) from the fourth year after diagnosis (adjusted HR, 2.11; 95% CI, 1.18-3.75), and this association attenuated after adjustment for second primary tumors. Every 10% sTIL increment was associated with 16% higher OS (adjusted HR, 0.84; 95% CI, 0.78-0.90) in gBRCA1m, sBRCA1m, or BRCA1-non-altered patients and 31% higher OS in tumor BRCA1-PM patients. Among the 66 patients with tumor BRCA1-PM and ≥ 50% sTILs, we observed excellent 15-year OS (97.0%; 95% CI, 92.9-100%). Conversely, among the 61 patients with gBRCA1m and < 50% sTILs, we observed poor 15-year OS (50.8%; 95% CI, 39.7-65.0%). Furthermore, gBRCA1m was associated with higher (adjusted subdistribution HR, 4.04; 95% CI, 2.29-7.13) and tumor BRCA1-PM with lower (adjusted subdistribution HR, 0.42; 95% CI, 0.19-0.95) incidence of second primary tumors, compared to BRCA1-non-alteration. Conclusions: Although both gBRCA1m and tumor BRCA1-PM alter BRCA1 gene transcription, they are associated with different outcomes in young, node-negative, chemotherapy-naïve TNBC patients. By combining sTILs and BRCA1 status for risk classification, we were able to identify potential subgroups in this population to intensify and optimize adjuvant treatment.
MeSH term(s)	Humans ; Female ; Adult ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/genetics ; Neoplasms, Second Primary ; Adjuvants, Immunologic ; Ethnicity ; Biomarkers ; BRCA1 Protein/genetics
Chemical Substances	Adjuvants, Immunologic ; Biomarkers ; BRCA1 protein, human ; BRCA1 Protein
Language	English
Publishing date	2024-01-09
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2131669-7
ISSN	1741-7015 ; 1741-7015
ISSN (online)	1741-7015
ISSN	1741-7015
DOI	10.1186/s12916-023-03233-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).

The British journal of surgery

2024 Volume 111, Issue 4

Abstract: Background: Trials have demonstrated the safety of omitting completion axillary lymph node dissection in patients with cT1-2 N0 breast cancer operated with breast-conserving surgery who have limited metastatic burden in the sentinel lymph node. The aim ... ...

Abstract	Background: Trials have demonstrated the safety of omitting completion axillary lymph node dissection in patients with cT1-2 N0 breast cancer operated with breast-conserving surgery who have limited metastatic burden in the sentinel lymph node. The aim of this registry study was to provide insight into the oncological safety of omitting completion axillary treatment in patients operated with mastectomy who have limited-volume sentinel lymph node metastasis. Methods: Women diagnosed in 2013-2014 with unilateral cT1-2 N0 breast cancer treated with mastectomy, with one to three sentinel lymph node metastases (pN1mi-pN1a), were identified from the Netherlands Cancer Registry, and classified by axillary treatment: no completion axillary treatment, completion axillary lymph node dissection, regional radiotherapy, or completion axillary lymph node dissection followed by regional radiotherapy. The primary endpoint was 5-year regional recurrence rate. Secondary endpoints included recurrence-free interval and overall survival, among others. Results: In total, 1090 patients were included (no completion axillary treatment, 219 (20.1%); completion axillary lymph node dissection, 437 (40.1%); regional radiotherapy, 327 (30.0%); completion axillary lymph node dissection and regional radiotherapy, 107 (9.8%)). Patients in the group without completion axillary treatment had more favourable tumour characteristics and were older. The overall 5-year regional recurrence rate was 1.3%, and did not differ significantly between the groups. The recurrence-free interval was also comparable among groups. The group of patients who did not undergo completion axillary treatment had statistically significantly worse 5-year overall survival, owing to a higher percentage of non-cancer deaths. Conclusion: In this registry study of patients with cT1-2 N0 breast cancer treated with mastectomy, with low-volume sentinel lymph node metastasis, the 5-year regional recurrence rate was low and comparable between patients with and without completion axillary treatment.
MeSH term(s)	Humans ; Female ; Sentinel Lymph Node Biopsy ; Breast Neoplasms/pathology ; Mastectomy ; Lymphatic Metastasis/pathology ; Lymph Node Excision ; Sentinel Lymph Node/pathology ; Mastectomy, Segmental ; Axilla/pathology ; Registries ; Lymph Nodes/surgery ; Lymph Nodes/pathology
Language	English
Publishing date	2024-04-10
Publishing country	England
Document type	Journal Article
ZDB-ID	2985-3
ISSN	1365-2168 ; 0263-1202 ; 0007-1323 ; 1355-7688
ISSN (online)	1365-2168
ISSN	0263-1202 ; 0007-1323 ; 1355-7688
DOI	10.1093/bjs/znae077
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.66: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito